St. Antonius Hospital
Nieuwegein, Utrecht, 3435 CM, Netherlands
Location status: Recruiting
NCT Number: NCT06603454
Rationale When determining the strategy for aortic valve replacement, echocardiography is still considered the golden standard (1). While pre-procedural MSCT is standard of care in TAVR patients, this is not yet part of routine clinical practice in SAVR patients. The researchers hypothesise that when atherosclerosis of the ascending aorta is identified preoperatively on contrast-enhanced multi-slice computed tomography (MSCT), the subclinical perioperative stroke rate (as detected on diffusion-weighted magnetic resonance imaging (DW-MRI)) can be reduced by modification of the operative strategy if necessary.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Nieuwegein, Utrecht, 3435 CM, Netherlands
Location status: Recruiting
When determining the strategy for aortic valve replacement, echocardiography is still considered the golden standard (1). While pre-procedural MSCT is standard of care in TAVR patients, this is not yet part of routine clinical practice in SAVR patients. The investigators hypothesise that when atherosclerosis of the ascending aorta is identified preoperatively on contrast-enhanced multi-slice computed tomography (MSCT), the subclinical perioperative stroke rate (as detected on diffusion-weighted magnetic resonance imaging (DW-MRI)) can be reduced by modification of the operative strategy if necessary.
The primary objective is to assess whether the use of pre-operative MSCT will reduce subclinical stroke rates (i.e., ischemic brain lesions) as identified with the use of DW-MRI after SAVR with or without concomitant CABG surgery.
The secondary objective is to assess whether the use of pre-operative MSCT will improve neurological assessment score, reduce clinical stroke, mortality, change in intervention strategy (pre- or intra-operatively), cannulation strategy and clamping strategy as well as reduce procedural times and improve quality of life (with the application of EQ-5D and KCCQ questionnaires).
This is a prospective, multicenter, parallel, open-label randomized controlled trial (RCT) with a 1:1 randomization including patients aged 18 years and older accepted for SAVR with or without concomitant CABG by the Heart Team at the St. Antonius Hospital Nieuwegein. All patients enrolled in the study will be randomized to additional pre-operative MSCT or no additional pre-operative MSCT. Postoperatively, a DW-MRI will be made in all patients. The trial will end after 30-day follow-up of all enrolled patients.
The main primary endpoint is the incidence of subclinical stroke rate (i.e., presence of new ischemic brain lesions) as identified with the use of DW-MRI made within one week postoperatively or before discharge. Secondary endpoints include the National Institutes of Health Stroke Scale (NIHSS) score within one week postoperatively (targeted at day two postoperatively), clinical ischemic stroke (conform VARC-3),transient ischemic attack diagnosed by a neurologist within one week postoperatively, defined by transient focal neurological signs or symptoms lasting < 24 h presumed to be due to focal brain, spinal cord or retinal ischemia, but without evidence of acute infarction by neuroimaging or pathology, or with no imaging performed (conform VARC-3), mortality at discharge (normally at three to five days postoperatively) or within one week postoperatively (if discharge is > 1 week postoperatively) and at three months postoperatively, the change in intervention strategy, the change in cannulation strategy, the change in clamping strategy, procedural times and the quality of life at three months postoperatively (assessed by EQ-5D and KCCQ)
When severe calcification of the ascending aorta is identified preoperatively on multi-slice computed tomography (MSCT), the operative strategy can be modified if necessary. This could possibly prevent stroke or even mortality in the study patients randomized to additional pre-operative MSCT. The MSCT will take 5-10 minutes. Only low-dose contrast-enhanced CT will be used, which results in a very low radiation risk. With application of too high dosages of contrast, there is a slight chance of kidney insufficiency. Furthermore, an allergic reaction to contrast could occur. However, patients with known allergies to contrast and patients with low renal function will be excluded from participation in this trial.
The patients receiving a preoperative CT-scan will have to be informed about all incidental findings found on the CT-scan. A possible disadvantage is found in the additional costs of a CT-scan, but the costs associated with stroke would outweigh the costs of a preoperative CT-scan. All patients will receive a DW-MRI before discharge. Contra-indications for MRI include pacemaker wires or implantable cardioverter defibrillators (ICDs), metallic implants, cochlear/ear implants, Swan-Ganz catheter, claustrophobia and contrast allergy. The presence of an aortic valve prosthesis is not a contra-indication for DW-MRI scanning.
All patients will be asked to fill out a questionnaire at baseline and within 90 days postoperatively. Since this will soon be implemented as part of standard care, the latter is not seen as extra burden for the patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Preoperative contrast enhanced CT
Time frame: Within 90 days post procedure
Subclinical stroke rate (i.e., presence of new ischemic brain lesions) as identified with the use of DW-MRI made within one week postoperatively or before discharge (in case of prolonged ICU stay).
Time frame: within one week postoperatively (targeted at day two postoperatively)
National Institutes of Health Stroke Scale, ranging 0 - 42. Higher scores refer to a more severe stroke.
Time frame: Within one week postoperatively
The incidence of clinical ischemic stroke (conform VARC-3) diagnosed by a neurologist within one week postoperatively, defined by the acute onset of focal neurological signs or symptoms conforming to a focal or multifocal vascular territory within the brain, spinal cord or retina and fulfilling one of the following criteria:
Time frame: One week postoperatively
The incidence of TIA diagnosed by a neurologist within one week postoperatively, defined by transient focal neurological signs or symptoms lasting < 24 h presumed to be due to focal brain, spinal cord or retinal ischemia, but without evidence of acute infarction by neuroimaging or pathology, or with no imaging performed (conform VARC-3).
Time frame: After hospital admission but before the end of surgery
Change in intervention strategy (no unfavourable change, cancellation of surgery, switch to TAVR preprocedural, conversion from limited access to conventional full median sternotomy, conversion to TAVR)
Time frame: During procedure
Change in cannulation strategy (no change, use of different cannula, avoiding cannulation of the ascending aorta/arch (thus femoral or subclavian cannulation), higher cannulation (arch), lower cannulation, echo-guided cannulation)
Time frame: During procedure
Change in clamping strategy (no change, change of clamping site, no clamping)
Time frame: During procedure
Implantation time (defined period from start of the first suture until the completion of the prosthesis implantation = fixation of last suture), surgical time, aortic cross-clamp (ACC) time, cardio-pulmonary bypass (CPB) time. All times in minutes.
Time frame: At baseline (prior to procedure) and 90 days post procedure
All scores are represented on a 0-to-100-point scale. Higher score refers to preferabel outcomes.
Contact information is provided by the study sponsor or research team.
Romy Hegeman, MD
CONTACT
Simon van Putten, MD
CONTACT
Romy Hegeman
Other
Preoperative Chest CT-imaging in Surgical Aortic Valve Replacement with or Without CABG: a Randomized Controlled Trial
Acronym: GUIDE-SAVR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05283356
Aortic Valve Disease, Aortic Valve Stenosis
Vigo, Pontevedra, Spain
View Trial DetailsNCT05172973
Aortic Valve Disease, Aortic Valve Insufficiency
Newport Beach, California, United States
View Trial DetailsNCT06773780
Aortic Valve Disease, Aortic Valve Stenosis
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07709858
Aortic Valve Disease, Aortic Valve Stenosis
Seoul, South Korea
View Trial Details